- Conditions
- Untreated Follicular Lymphoma
- Interventions
- Surovatamig, R-CHOP, R-CVP, BR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more
- Conditions
- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 18 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 14
- States / cities
- La Jolla, California • Denver, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Interventions
- Surovatamig
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Fullerton, California • St Louis, Missouri + 2 more
- Conditions
- B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 19 more
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
- Interventions
- Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Iowa City, Iowa • Bethesda, Maryland + 2 more